PURPOSE: Prospective pilot study to assess patient outcome after stereotactic body radiation therapy (SBRT) for limited metastases from breast cancer. METHODS: Forty patients with < or =5 metastatic lesions received curative-intent SBRT, while 11 patients with >5 lesions, undergoing SBRT to < or =5 metastatic lesions, were treated with palliative-intent. RESULTS: Among those treated with curative-intent, 4-year actuarial outcomes were: overall survival of 59%, progression-free survival of 38% and lesion local control of 89%. On univariate analyses, 1 metastatic lesion (versus 2-5), smaller tumor volume, bone-only disease, and stable or regressing lesions prior to SBRT were associated with more favorable outcome. Patients treated with palliative-intent SBRT were spared morbidity and mortality from progression of treated lesions, though all developed further metastatic progression shortly (median 4 months) after enrollment. CONCLUSIONS: SBRT may yield prolonged survival and perhaps cure in select patients with limited metastases. Palliative-intent SBRT may be warranted for symptomatic or potentially symptomatic metastases.
PURPOSE: Prospective pilot study to assess patient outcome after stereotactic body radiation therapy (SBRT) for limited metastases from breast cancer. METHODS: Forty patients with < or =5 metastatic lesions received curative-intent SBRT, while 11 patients with >5 lesions, undergoing SBRT to < or =5 metastatic lesions, were treated with palliative-intent. RESULTS: Among those treated with curative-intent, 4-year actuarial outcomes were: overall survival of 59%, progression-free survival of 38% and lesion local control of 89%. On univariate analyses, 1 metastatic lesion (versus 2-5), smaller tumor volume, bone-only disease, and stable or regressing lesions prior to SBRT were associated with more favorable outcome. Patients treated with palliative-intent SBRT were spared morbidity and mortality from progression of treated lesions, though all developed further metastatic progression shortly (median 4 months) after enrollment. CONCLUSIONS: SBRT may yield prolonged survival and perhaps cure in select patients with limited metastases. Palliative-intent SBRT may be warranted for symptomatic or potentially symptomatic metastases.
Authors: Davide Franceschini; Ciro Franzese; Fiorenza De Rose; Pierina Navarria; Giuseppe R D'Agostino; Tiziana Comito; Angelo Tozzi; Maria C Tronconi; Lorenza Di Guardo; Michele Del Vecchio; Marta Scorsetti Journal: Br J Radiol Date: 2017-07-14 Impact factor: 3.039
Authors: David A Palma; Joseph K Salama; Simon S Lo; Suresh Senan; Tom Treasure; Ramaswamy Govindan; Ralph Weichselbaum Journal: Nat Rev Clin Oncol Date: 2014-06-24 Impact factor: 66.675
Authors: Andrew J Johnsrud; Samir V Jenkins; A Jamshidi-Parsian; Charles M Quick; Edvaldo P Galhardo; Ruud P M Dings; Kieng B Vang; Ganesh Narayanasamy; Issam Makhoul; Robert J Griffin Journal: Radiat Res Date: 2020-12-01 Impact factor: 2.841